Table A1.
IGF-IR Biomarker Percent Change From Baseline to Week 12
| Biomarker Measure (% Δ) | AD Plus Cixutumumab (n = 18) |
AD Alone (n = 9) |
P* | ||
|---|---|---|---|---|---|
| Median | Range | Median | Range | ||
| C-peptide† | 12 | 376.9 | −17 | 560.0 | .67 |
| IGFBP-I† | −24 | 117.5 | 33 | 622.3 | .29 |
| IGFBP-III† | 11 | 216.5 | −4 | 77.4 | .15 |
| IGF-I | 4 | 2,137.7 | 4 | 222.1 | .98 |
| IGF-II | −2 | 172.7 | −10 | 112.8 | .21 |
| GH† | 77 | 1,672.0 | −23 | 536.2 | .53 |
| Insulin | −2 | 239.4 | −1 | 128.8 | .82 |
Abbreviations: AD, androgen deprivation; BP, binding protein; GH, growth hormone; IGF, insulin-like growth factor; IGF-IR, insulin-like growth factor I receptor.
*
Two-sided Wilcoxon rank sum test.
†
n = 17.